Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol...
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present a...
CAMBRIDGE, Mass., May 23, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host an analyst/investor event and webcast on June ...
Gainers: Can-Fite BioPharma (NYSEMKT: CANF ) +38% . Outlook Therapeutics (NASDAQ: OTLK ) +30% . Del Frisco's Restaurant Group (NASDAQ: DFRG ) +27% . Orion Energy Systems (NASDAQ: OESX ) +23% . Sprint Corporation (NYSE: S ) +22% . ENDRA Life Sciences (NASDAQ: NDRA ) +18% . Sesen...
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller, Senior Scientist at Constellation Pharmaceuticals, presented a poster titled Targeting epigenetic dysregulation in bladder cancer through...
The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am...
Data published in two abstracts suggest that CPI-0610 may have potential disease-modifying effects in treating myelofibrosis All ten evaluable patients experienced spleen volume reductions Improvements in symptom scores, bone marrow fibrosis, and hemoglobin levels also seen Tw...
Constellation Pharmaceuticals (NASDAQ: CNST ): Q1 GAAP EPS of -$0.75 beats by $0.06 . Cash and cash equivalents of $115.8M Press Release More news on: Constellation Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Company to present an interim update of data from the MANIFEST clinical trial of CPI-0610 at ASCO on June 3 and at EHA on June 15 Related investor event at ASCO to be held on June 4 CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Na...
CAMBRIDGE, Mass., April 19, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will be participa...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...